A SYSTEMATIC REVIEW ON CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i12.47889Keywords:
Acquired thrombotic thrombocytopenic purpura, Plasma exchange, CaplacizumabAbstract
A systematic review of literature addressing the efficacy and safety of caplacizumab for patients with acquired thrombotic thrombocytopenic purpura (aTTP) was done. The literature search for 5 years (2017–2021) was conducted using particular search terms in databases/search engines (PubMed, Cochrane), and articles were screened based on inclusion and exclusion criteria. A total of 394 peoples were involved in the selected studies. With caplacizumab, the median time to normalization of the platelet count was faster than with a placebo. In comparison to those who received a placebo, patients who received caplacizumab required fewer plasma exchanges and spent less time in the hospital. Mucocutaneous bleeding was reported by 65% of participants receiving caplacizumab and 48% of patients receiving a placebo as the most frequent side effect. Three patients died in the placebo group. After the trial period, one patient died due to cerebral ischemia in the caplacizumab group. Caplacizumab was efficacious and well tolerated in patients with aTTP who experienced a diseases exacerbation.
Downloads
References
Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017;129:2836-46. doi: 10.1182/blood-2016-10-709857, PMID: 28416507
Sadler JE. What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2015;2015:631-6. doi: 10.1182/asheducation-2015.1.631, PMID: 26637781
Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158:323-35. doi: 10.1111/j.1365-2141.2012.09167.x, PMID: 22624596
Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008;112:11-8. doi: 10.1182/ blood-2008-02-078170, PMID: 18574040
Sarig G. ADAMTS-13 in the diagnosis and management of thrombotic microangiopathies. Rambam Maimonides Med J 2014;5:e0026. doi: 10.5041/RMMJ.10160, PMID: 25386342
Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, BoisseauṣP, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 2016;3:e237-45. doi: 10.1016/S2352-3026(16)30018-7, PMID: 27132698
Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, Szczepiorkowski ZM, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014;29:148-67. doi: 10.1002/jca.21302, PMID: 24136342
Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, et al. Regional UK TTP registry: Correlation with laboratory ADAMTS13 analysis and clinical features. Br J Haematol 2008;142:819-26. doi: 10.1111/j.1365-2141.2008.07276.x, PMID: 18637802
Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, et al. Thrombotic thrombocytopenic purpura in black people: Impact of ethnicity on survival and genetic risk factors. PLoS One 2016;11:e0156679. doi: 10.1371/journal.pone.0156679, PMID: 27383202
Patschan D, Witzke O, Dührsen U, Erbel R, Philipp T, Herget-Rosenthal S. Acute myocardial infarction in thrombotic microangiopathies - clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 2006;21:1549-54. doi: 10.1093/ndt/gfl127, PMID: 16574680
Nichols L, Berg A, Rollins-Raval MA, Raval JS. Cardiac injury is a common postmortem finding in thrombotic thrombocytopenic purpura patients: Is empiric cardiac monitoring and protection needed? Ther Apher Dial 2015;19:87-92. doi: 10.1111/1744-9987.12191, PMID: 25196220
Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood 2017;130:1181-8. doi: 10.1182/blood-2017-04-636431, PMID: 28768626
Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008;93:232-9. doi: 10.3324/ haematol.11739, PMID: 18223285
Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589- 600. doi: 10.1056/NEJMra020528, PMID: 12192020
Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011;118:757-65. doi: 10.1182/ blood-2010-11-317859, PMID: 21576702
Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, et al. Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost 2020;18:479-84. doi: 10.1111/jth.14679, PMID: 31691462
Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016;374:511-22. doi: 10.1056/NEJMoa1505533, PMID: 26863353
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019;380:335-46. doi: 10.1056/NEJMoa1806311, PMID: 30625070
Estcourt LJ. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial). Transfus Med 2019;29:146-8. doi: 10.1111/tme.12615, PMID: 31318128
Peyvandi F, Scully M, Kremer Hovinga JA, Knöbl P, Cataland S, De Beuf K, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2017;15:1448-52. doi: 10.1111/jth.13716, PMID: 28445600
Published
How to Cite
Issue
Section
Copyright (c) 2023 Jayasutha Jayram, MUTHU KARUPPEE KANNAN, LOKESH KUMAR DHAVANAM RAMESH BABU, LOKESHWAR VIJAYAGANAPATHY, RUBAK KUMARAN MYLAINATHAN, DENNIS WIN MIN TUN
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
